Autopsy and brain donation: more detail

What does the consent actually decide?

Three separate things, and they are often presented as one.

The first is whether an examination takes place at all. The second is whether the brain may be retained for prolonged fixation. The 2026 UK recommendations state that consent should ideally allow this, because prolonged fixation improves the chance of reaching a diagnosis. The third is what happens to the tissue afterwards: it can be returned to the family, disposed of by the hospital, or donated for research or education, according to what the consent specifies.

Where the brain needs to go back to the body before the funeral, the recommendations describe an alternative: sampling from a fresh brain. That preserves the funeral timetable and gives up the diagnostic advantage of prolonged fixation. A family that is told only about the first option has not been given the choice that exists.

Why the laboratory timeline is what it is

Analysis is performed in a containment level 3 laboratory, and the 2026 recommendations state it can take up to three months. The US national centre gives the same figure for release of final reports, at about three months after the autopsy. That is the realistic figure to give a family, and it is worth saying out loud early, because a family expecting a result in weeks will often conclude that something has gone wrong.

Who receives the result

In the United States the centre reports only to the physicians named on the brain-only autopsy consent form and states it cannot release results directly to family members. Those physicians are expected to discuss the findings with the family. Two practical consequences follow. Whoever is named on the form needs to be a clinician who will still be reachable in three months, and the family needs that name recorded somewhere they can find it. A named clinician who has moved post, or a hospital team with no continuing involvement, is the commonest reason a family is left without an explanation of a report that was in fact issued.

Handling and precautions

The 2026 recommendations state that routine handling of the body follows standard precautions, and that prion disease is not thought to spread through everyday social or clinical contact. Extra precautions apply to procedures involving high-infectivity tissue, specifically brain, spinal cord and posterior eye. A dedicated high-risk post-mortem suite is preferred, and a general hospital suite can be used with added health and safety measures.

Two points are worth being able to state plainly. People with prion disease, and people at increased risk, cannot donate blood or organs, and should tell their care team before any medical or dental procedure. And families who wish to see or touch the body should be supported in doing so, ideally before the post-mortem, since appearance may change afterwards.

In England the ACDP guidance set published by the Department of Health and Social Care includes annexes for pathology and for care after death, and an information sheet written for funeral directors and relatives. That sheet is the document to put in front of a funeral director who is uncertain about embalming or viewing, rather than arguing the point from first principles.

How often does this come up now?

Less often than it did. The UK surveillance unit’s annual report covering 1990 to 2023 records that autopsy rates in suspected CJD cases have fallen, while the unit still obtains detailed clinical and epidemiological information for most patients, and earlier reports note the decline tracks general UK autopsy trends. The 2026 recommendations give the reason from the clinical side: MRI and CSF RT-QuIC have improved diagnostic confidence in life and reduced the need for a post-mortem.

The practical effect is that a family being asked today is more often being asked about certainty, subtype, genetic testing where no blood sample was taken, and research donation, rather than about establishing the diagnosis. Framing the conversation that way is more accurate than presenting it as the test that will finally give the answer.

When the question is research donation

Donation for research is a separate decision from diagnostic examination, and the consent specifies it. Declining research use while agreeing to the examination is a coherent position, and so is the reverse where the family wants tissue to be useful but has no need of a subtype result. Where donated tissue goes is described on brain and tissue banks. The clinical pathway, contacts and country routes are on autopsy and confirmation.